CKS1B

Summary

CKS1B (CDC28 protein kinase regulatory subunit 1B, HGNC:19083) is a protein-coding gene on chromosome 1q21.3, encoding Cyclin-dependent kinases regulatory subunit 1 (P61024). Binds to the catalytic subunit of the cyclin dependent kinases and is essential for their biological function. It is a selective cancer dependency (DepMap: 77.8% of cell lines).

CKS1B protein binds to the catalytic subunit of the cyclin dependent kinases and is essential for their biological function. The CKS1B mRNA is found to be expressed in different patterns through the cell cycle in HeLa cells, which reflects a specialized role for the encoded protein. At least two transcript variants have been identified for this gene, and it appears that only one of them encodes a protein.

Source: NCBI Gene 1163 — RefSeq curated summary.

At a glance

• GWAS associations: 8
• Clinical variants (ClinVar): 9 total — 2 pathogenic
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• Cancer dependency (DepMap): dependent in 77.8% of screened cell lines
• MANE Select transcript: NM_001826

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:19083
Approved symbol	CKS1B
Name	CDC28 protein kinase regulatory subunit 1B
Location	1q21.3
Locus type	gene with protein product
Status	Approved
Aliases	ckshs1, CKS1
Ensembl gene	ENSG00000173207
Ensembl biotype	protein_coding
OMIM	116900
Entrez	1163

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 5 protein_coding, 4 protein_coding_CDS_not_defined

ENST00000308987, ENST00000368436, ENST00000368439, ENST00000471245, ENST00000473344, ENST00000474215, ENST00000477676, ENST00000913207, ENST00000913208

RefSeq mRNA: 1 — MANE Select: NM_001826 NM_001826

CCDS: CCDS1077

Canonical transcript exons

ENST00000308987 — 3 exons

Exon	Start	End
ENSE00001200321	154974681	154974804
ENSE00001848352	154978725	154979251
ENSE00003557212	154977987	154978114

Expression profiles

Bgee: expression breadth ubiquitous, 141 present calls, max score 98.28.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 29.0768 / max 346.0249, expressed in 1749 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
5545	22.3388	1708
5544	5.9062	1362
5546	0.8318	422

Top tissues by expression

141 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ventricular zone	UBERON:0003053	98.28	gold quality
ganglionic eminence	UBERON:0004023	97.58	gold quality
lymph node	UBERON:0000029	96.02	gold quality
mucosa of transverse colon	UBERON:0004991	95.79	gold quality
placenta	UBERON:0001987	95.63	gold quality
rectum	UBERON:0001052	95.52	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	95.23	gold quality
subcutaneous adipose tissue	UBERON:0002190	94.99	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	94.86	gold quality
esophagus mucosa	UBERON:0002469	94.81	gold quality
testis	UBERON:0000473	94.73	gold quality
left testis	UBERON:0004533	94.71	gold quality
mammary gland	UBERON:0001911	94.70	gold quality
thoracic mammary gland	UBERON:0005200	94.70	gold quality
right testis	UBERON:0004534	94.69	gold quality
skin of abdomen	UBERON:0001416	94.68	gold quality
islet of Langerhans	UBERON:0000006	94.58	gold quality
adipose tissue	UBERON:0001013	94.55	gold quality
zone of skin	UBERON:0000014	94.41	gold quality
skin of leg	UBERON:0001511	94.27	gold quality
right lobe of liver	UBERON:0001114	94.13	gold quality
lower esophagus mucosa	UBERON:0035834	94.12	gold quality
duodenum	UBERON:0002114	94.07	gold quality
omental fat pad	UBERON:0010414	93.99	gold quality
right coronary artery	UBERON:0001625	93.89	gold quality
bone marrow	UBERON:0002371	93.83	gold quality
stromal cell of endometrium	CL:0002255	93.81	gold quality
popliteal artery	UBERON:0002250	93.76	gold quality
tibial artery	UBERON:0007610	93.76	gold quality
artery	UBERON:0001637	93.67	gold quality

Single-cell (SCXA)

Detected in 34 experiment(s), a significant marker in 28.

Experiment	Marker?	Max mean expression
E-MTAB-10485	yes	1060.71
E-MTAB-6911	yes	879.94
E-MTAB-6108	yes	702.32
E-MTAB-11121	yes	692.15
E-MTAB-9154	yes	666.43
E-MTAB-6505	yes	638.45
E-HCAD-13	yes	555.54
E-GEOD-93593	yes	521.17
E-MTAB-9435	yes	468.71
E-GEOD-110499	yes	403.44
E-MTAB-8142	yes	388.41
E-MTAB-7052	yes	331.69
E-MTAB-6379	yes	283.46
E-HCAD-29	yes	203.73
E-MTAB-6701	yes	74.40

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): FOXM1, GLI2, TP53, TP63, TP73

miRNA regulators (miRDB)

40 targeting CKS1B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-3119	99.92	71.34	2390
HSA-MIR-605-3P	99.88	69.22	1833
HSA-MIR-8080	99.82	67.52	1342
HSA-MIR-4694-3P	99.79	69.53	2640
HSA-MIR-494-3P	99.70	71.45	2795
HSA-MIR-3975	99.62	65.97	697
HSA-MIR-548AH-5P	99.52	69.73	2626
HSA-MIR-578	99.46	68.36	1787
HSA-MIR-2115-3P	99.31	69.68	2026
HSA-MIR-4505	99.27	67.81	2678
HSA-MIR-3064-5P	99.26	66.13	1497
HSA-MIR-3085-3P	99.26	66.16	1490
HSA-MIR-5787	99.22	67.86	2628
HSA-MIR-3973	99.20	69.19	1990
HSA-MIR-100-3P	99.20	67.33	672
HSA-MIR-196A-3P	99.19	67.34	1204
HSA-MIR-485-5P	99.10	64.78	1889
HSA-MIR-6884-5P	99.10	64.50	1987
HSA-MIR-371A-5P	99.08	66.51	1914
HSA-MIR-4478	99.07	65.16	2320
HSA-MIR-361-5P	98.95	70.16	1340
HSA-MIR-520G-3P	98.91	67.38	1914
HSA-MIR-520H	98.91	67.38	1914
HSA-MIR-374A-3P	98.87	67.82	1531
HSA-MIR-3922-5P	98.77	66.53	1059
HSA-MIR-3188	98.58	65.60	878

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 77.8% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 40)

• Weak cooperativity in the core causes a switch in folding mechanism between two proteins of the cks family. (PMID:12473461)
• induction of Skp2 and Cks1 degradation in G1 represents a principal mechanism by which APC/C(Cdh1) prevents the unscheduled degradation of SCF(Skp2-Cks1) substrates and maintains the G1 state (PMID:15014502)
• Cks1 overexpression may play an important role for oral squamous cell carcinoma development through Skp2-mediated p27 degradation (PMID:15579456)
• analysis of the protein dynamics of Cks1 (PMID:15772084)
• ubiquitin ligase subunit Cks1 is involved in p27Kip1 down-regulation and may have an important role in the development of aggressive tumor behavior in breast cancer. (PMID:16168119)
• over-expression of CKS1B, mainly due to gene amplification, imparts a poor prognosis in MM, possibly as a result of enhanced degradation of p27Kip1. (PMID:16188652)
• Cks1 expression level regulates melanoma cell growth, most likely through effects on cell proliferation. (PMID:16924241)
• Results show that complex formation between Cks1 and Skp2 causes conformational changes in both proteins in regions distant from the respective binding sites. (PMID:16979657)
• CKS1B influences myeloma cell growth and survival through SKP2- and p27(Kip1)-dependent and -independent mechanisms (PMID:17303695)
• Generally, the observation that the potential oncogene Cks1 is downregulated by the tumor suppressor p53 corresponds well with the idea that p53 employs multiple ways in order to halt the cell cycle. (PMID:17377499)
• Myc targets CKS1 to provoke the suppression of KIP1. (PMID:17464290)
• Data show that Cdc20 and Cks1 direct the spindle checkpoint-independent destruction of cyclin A2. (PMID:18471975)
• Cks1 expression was only correlated with tumor size in renal cell carcinoma. (PMID:18922157)
• These data suggest that Cks1 is an oncogene in the 1q21 amplicon and plays an important role for breast cancer development. (PMID:19161979)
• Data show that mtSSB bound both CKS1 and CKS2 and underwent CDK-dependent phosphorylation. (PMID:19786724)
• Overexpression of Cks1 and Cks2 is associated with the aggressive tumour behaviours of hepatocellular carcinoma. (PMID:19845855)
• CKS1B overexpression implicates clinical aggressiveness of hepatocellular carcinomas but not p27(Kip1) protein turnover. (PMID:19866239)
• CKS1B analysis predicts 1q21 amplification and adverse outcome for risk stratification of patients with multiple myeloma. (PMID:20421271)
• In addition to having a pivotal role in the up-regulation of IL-2 and IL-2RA gene expression, IKK controls the expression of cyclin D3, cyclin E and CDK2, and the stability SKP2 and its co-factor CKS1B, through mechanisms independent of IL-2. (PMID:20465575)
• CKS-1B is commonly expressed in mantle cell lymphoma, particularly in aggressive histologic variants, and may be involved in pathogenesis. (PMID:20688354)
• Data report that endogenous cyclin B1-Cdk1 is recruited in a Cks-dependent manner to checkpoint-inhibited, phosphorylated APC/C in prometaphase independently of Cdc20 or the cyclin B1 D box. (PMID:20733055)
• Association between CKS1B protein overexpression and both polysomy and amplification was demonstrated in cutaneous squamous cell carcinoma (PMID:20737481)
• Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance. (PMID:20930946)
• A significant CKS1B overexpression was observed in oral squamous cell carcinoma and lymph node metastases samples than in oral lichen planus or oral leukoplakia. (PMID:21117028)
• Overexpression of Cks1 or Cks2 in human mammary epithelial and breast cancer-derived cells, as well as in other cell types, leads to override of the intra-S-phase checkpoint. (PMID:21697511)
• In hepatoma cells, Cks1 controlled IL-8 expression by targeting the NF-kappaB regulator IkappaBalpha, which led to NF-kappaB activation, via a p27-independent regulation of IkappaB kinase complex components. (PMID:21917729)
• cyclin kinase subunit 1B nuclear expression detected by immunohistochemistry is an adverse prognostic factor for patients with multiple myeloma treated with bortezomib therapy (PMID:22047644)
• Cks1 is overexpressed in esophageal squamous cell carcinoma tissues. Overexpression correlates with increased radiotherapy resistance of esophageal squamous cell carcinoma. (PMID:22302047)
• CKS1 mRNA and protein expression were increased in esophageal carcinoma. Overexpression of CKS1 was associated with higher grad, regional lymph node invasion, and neoplastic embolus. CKS1 was negatively associated with the p27(kip1) level in the tumor. (PMID:23301842)
• We demonstrated that high expression of CKS1B immunostaining can be one potent prognostic factor for disease-specific survival, metastasis-free survival, and local recurrence-free survival in patients with nasopharyngeal carcinoma. (PMID:23879533)
• Anaplastic multiple myeloma was associated with significantly higher prevalence of CKS1B amplification than non-anaplastic multiple myeloma. (PMID:24169086)
• Specifically, CKS1B and MAP2K5 significantly inhibited hepatitis C viral RNA replication. PACSIN1, by contrast, inhibited hepatitis C virus infection by decreasing the level of viral protein p7. (PMID:24205826)
• EGF upregulates the mRNA and protein levels of Skp2/Cks1 and p27(kip1) via the PI3K/Akt pathway and direct binding of E2F1 transcription factor with the Skp2 promoter in extrahepatic cholangiocarcinoma cells. (PMID:24574749)
• Our results suggest a role for CKS1B in the multiple step process of progression of MGUS to MM and show that CKS1B copy gain has a more significant prognostic value than its overexpression. (PMID:24973170)
• Regulation of Cks1 protein stability is crucially dependent on specific tyrosine and lysine residues which are potential sites for post-translational modifications. (PMID:25353373)
• We conclude that perturbing the Hsp90 pathway could provide a useful therapeutic strategy in tumors driven by Cks1 overexpression (PMID:25544127)
• Results show that Cks1 and Cks2 promoted proliferation and prevented apoptosis of hepatocellular carcinoma HepG2 cells. (PMID:26531156)
• Loss of miR-1258 contributes to carcinogenesis and progression of liver cancer through targeting CKS1B. (PMID:27270326)
• we overexpressed CKS1B in multiple cell lines and found increased sensitivity to PLK1 knockdown and PLK1 drug inhibition. Finally, combined inhibition of WEE1 and PLK1 results in less apoptosis than predicted based on an additive model of the individual inhibitors, showing an epistatic interaction and confirming a prediction of the yeast data. (PMID:27558135)
• Multiple myeloma patients with CKS1B amplification are more likely to have additional high-risk cytogenetic abnormalities and a shorter PFS and OS after an auto-HCT. (PMID:27638366)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	cks1b	ENSDARG00000007971
mus_musculus	Cks1b	ENSMUSG00000028044
mus_musculus	Cks1brt	ENSMUSG00000062687
rattus_norvegicus	AABR07049223.1	ENSRNOG00000032516
drosophila_melanogaster	Cks85A	FBGN0037613
caenorhabditis_elegans		WBGENE00001051

Paralogs (2): CKS2 (ENSG00000123975), NIP7 (ENSG00000132603)

Protein

Protein identifiers

Cyclin-dependent kinases regulatory subunit 1 — P61024 (reviewed: P61024)

All UniProt accessions (4): P61024, Q5T178, Q5T179, Q9BZU3

UniProt curated annotations — full annotation on UniProt →

Function. Binds to the catalytic subunit of the cyclin dependent kinases and is essential for their biological function.

Subunit / interactions. Forms a homohexamer that can probably bind six kinase subunits.

Similarity. Belongs to the CKS family.

RefSeq proteins (1): NP_001817* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000789	Cyclin-dep_kinase_reg-sub	Family
IPR036858	Cyclin-dep_kinase_reg-sub_sf	Homologous_superfamily

Pfam: PF01111

UniProt features (12 total): strand 7, helix 2, initiator methionine 1, chain 1, modified residue 1

Structure

Experimental structures (PDB)

19 structures.

PDB	Method	Resolution (Å)
2AST	X-RAY DIFFRACTION	2.3
1BUH	X-RAY DIFFRACTION	2.6
4YC6	X-RAY DIFFRACTION	2.6
1DKT	X-RAY DIFFRACTION	2.9
9QO4	ELECTRON MICROSCOPY	2.95
2ASS	X-RAY DIFFRACTION	3
8OR0	ELECTRON MICROSCOPY	3.1
1DKS	X-RAY DIFFRACTION	3.2
9QO0	ELECTRON MICROSCOPY	3.26
8BYA	ELECTRON MICROSCOPY	3.38
8BYL	ELECTRON MICROSCOPY	3.5
7NJ0	ELECTRON MICROSCOPY	3.6
7B5L	ELECTRON MICROSCOPY	3.8
7B5R	ELECTRON MICROSCOPY	3.8
8OR4	ELECTRON MICROSCOPY	3.8
9QO2	ELECTRON MICROSCOPY	3.8
7B5M	ELECTRON MICROSCOPY	3.91
9QO5	ELECTRON MICROSCOPY	4
9QO3	ELECTRON MICROSCOPY	4.6

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P61024-F1	92.27	0.86

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 2

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-187577	SCF(Skp2)-mediated degradation of p27/p21
R-HSA-69231	Cyclin D associated events in G1

MSigDB gene sets: 413 (showing top): AHRARNT_01, GNF2_CKS1B, BORCZUK_MALIGNANT_MESOTHELIOMA_UP, HORIUCHI_WTAP_TARGETS_DN, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP, CCAWYNNGAAR_UNKNOWN, GAANYNYGACNY_UNKNOWN, PAL_PRMT5_TARGETS_UP, CROONQUIST_NRAS_SIGNALING_DN, HOFMANN_CELL_LYMPHOMA_UP, REACTOME_SCF_SKP2_MEDIATED_DEGRADATION_OF_P27_P21, MATTIOLI_MGUS_VS_PCL, MAZ_Q6, FRASOR_RESPONSE_TO_SERM_OR_FULVESTRANT_DN, GGGTGGRR_PAX4_03

GO Biological Process (2): regulation of mitotic cell cycle (GO:0007346), cell division (GO:0051301)

GO Molecular Function (7): protein kinase binding (GO:0019901), histone binding (GO:0042393), ubiquitin binding (GO:0043130), cyclin-dependent protein serine/threonine kinase activator activity (GO:0061575), protein binding (GO:0005515), kinase activity (GO:0016301), cyclin-dependent protein serine/threonine kinase regulator activity (GO:0016538)

GO Cellular Component (3): cyclin-dependent protein kinase holoenzyme complex (GO:0000307), nucleoplasm (GO:0005654), SCF ubiquitin ligase complex (GO:0019005)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Cyclin E associated events during G1/S transition	1
Cyclin A:Cdk2-associated events at S phase entry	1
G1 Phase	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cyclin-dependent protein serine/threonine kinase activity	2
mitotic cell cycle	1
regulation of cell cycle	1
cellular process	1
kinase binding	1
protein binding	1
ubiquitin-like protein binding	1
cyclin-dependent protein serine/threonine kinase regulator activity	1
protein serine/threonine kinase activator activity	1
binding	1
transferase activity, transferring phosphorus-containing groups	1
cyclin-dependent protein kinase regulator activity	1
serine/threonine protein kinase complex	1
nuclear lumen	1
cellular anatomical structure	1
cullin-RING ubiquitin ligase complex	1

Protein interactions and networks

STRING

0 interactions, top by confidence (×1000):

IntAct

266 interactions, top by confidence:

A	B	Type	Score
CKS1B	CDK2	psi-mi:“MI:0915”(physical association)	0.950
CDK2	CKS1B	psi-mi:“MI:2364”(proximity)	0.950
CDK2	CKS1B	psi-mi:“MI:0915”(physical association)	0.950
CDK2	CCNE2	psi-mi:“MI:0914”(association)	0.940
CDK1	CKS1B	psi-mi:“MI:0915”(physical association)	0.920
CDK2	CCNB1	psi-mi:“MI:0914”(association)	0.890
CDK1	CCNB2	psi-mi:“MI:0914”(association)	0.840
CKS1B	CDK3	psi-mi:“MI:0915”(physical association)	0.800
CKS1B	XIAP	psi-mi:“MI:0915”(physical association)	0.780
XIAP	CKS1B	psi-mi:“MI:0915”(physical association)	0.780
TRIM49	CKS1B	psi-mi:“MI:0914”(association)	0.740
TRIM49	CKS1B	psi-mi:“MI:0915”(physical association)	0.740
COPS6	RHOBTB1	psi-mi:“MI:0914”(association)	0.730

BioGRID (218): CKS1B (Two-hybrid), CKS1B (Two-hybrid), CKS1B (Two-hybrid), CKS1B (Two-hybrid), KRTAP5-9 (Two-hybrid), MEOX1 (Two-hybrid), REL (Two-hybrid), TRIM27 (Two-hybrid), TCF4 (Two-hybrid), IKZF1 (Two-hybrid), ARID5A (Two-hybrid), ROPN1 (Two-hybrid), SEPT3 (Two-hybrid), MIPOL1 (Two-hybrid), SPERT (Two-hybrid)

ESM2 similar proteins: A0KK58, A0KXU1, A1RK88, A2XCH8, A4VJA8, A4Y6A8, A8XMF2, B0G102, G5EDM7, O04438, O23249, O94733, P00128, P0CM26, P0CM27, P12798, P16653, P20329, P20486, P23915, P28896, P28974, P33552, P37991, P55933, P56390, P61024, P61025, P84395, Q07088, Q0P5A5, Q0TBK7, Q15S25, Q17868, Q1R4Z6, Q24152, Q2KJI1, Q3M6B5, Q6C3T0, Q6PS57

Diamond homologs: A2XCH8, A8XMF2, B0G102, O23249, P08463, P20486, P33552, P41384, P55933, P56390, P61024, P61025, Q0P5A5, Q17868, Q24152, Q25330, Q2KJI1, Q6PS57, Q91879, Q9SJJ5

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 78 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
TP53 Regulates Transcription of Cell Cycle Genes	8	94.6×	3e-12
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest	6	93.1×	1e-09
p53-Dependent G1 DNA Damage Response	6	93.1×	1e-09
p53-Dependent G1/S DNA damage checkpoint	6	93.1×	1e-09
G1/S DNA Damage Checkpoints	6	87.6×	2e-09
Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)	5	69.0×	2e-07
G0 and Early G1	5	47.7×	8e-07
Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins	5	44.3×	1e-06

GO biological processes:

GO term	Partners	Fold	FDR
G1/S transition of mitotic cell cycle	11	33.4×	1e-11
G2/M transition of mitotic cell cycle	5	23.6×	4e-04
cell division	10	7.0×	4e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

9 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	0
Uncertain significance	4
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
1706624	NM_001826.3(CKS1B):c.33del (p.Lys11fs)	Pathogenic
1706625	NM_001826.3(CKS1B):c.51del (p.Phe17fs)	Pathogenic

SpliceAI

361 predictions. Top by Δscore:

Variant	Effect	Δscore
1:154974791:GAGTT:G	donor_gain	1.0000
1:154977985:A:AG	acceptor_gain	1.0000
1:154977986:G:GG	acceptor_gain	1.0000
1:154977986:GAC:G	acceptor_gain	1.0000
1:154977986:GACAT:G	acceptor_gain	1.0000
1:154974795:T:TG	donor_gain	0.9900
1:154977979:T:A	acceptor_gain	0.9900
1:154977981:TTACA:T	acceptor_loss	0.9900
1:154977982:TACA:T	acceptor_loss	0.9900
1:154977983:ACAGA:A	acceptor_loss	0.9900
1:154977984:CAG:C	acceptor_loss	0.9900
1:154977985:A:T	acceptor_loss	0.9900
1:154977986:G:GT	acceptor_loss	0.9900
1:154977986:GA:G	acceptor_gain	0.9900
1:154977986:GACA:G	acceptor_gain	0.9900
1:154978084:GGA:G	donor_gain	0.9900
1:154978085:G:T	donor_gain	0.9900
1:154978110:ACCAG:A	donor_loss	0.9900
1:154978111:CCAGG:C	donor_loss	0.9900
1:154978112:CAGGT:C	donor_loss	0.9900
1:154978113:AGGTC:A	donor_loss	0.9900
1:154978114:GGT:G	donor_loss	0.9900
1:154978115:G:T	donor_loss	0.9900
1:154978116:T:A	donor_loss	0.9900
1:154974793:GTT:G	donor_gain	0.9800
1:154974794:TTT:T	donor_gain	0.9800
1:154974795:T:G	donor_gain	0.9800
1:154974805:G:GG	donor_gain	0.9800
1:154974799:G:GG	donor_gain	0.9700
1:154974803:CGG:C	donor_loss	0.9700

AlphaMissense

521 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:154978054:T:A	W43R	1.000
1:154978054:T:C	W43R	1.000
1:154978058:G:C	R44T	1.000
1:154978058:G:T	R44M	1.000
1:154978059:G:C	R44S	1.000
1:154978059:G:T	R44S	1.000
1:154978087:T:A	W54R	1.000
1:154978087:T:C	W54R	1.000
1:154978089:G:C	W54C	1.000
1:154978089:G:T	W54C	1.000
1:154974767:T:C	Y8H	0.999
1:154974779:T:C	Y12H	0.999
1:154974804:G:C	R20P	0.999
1:154977992:T:A	V22D	0.999
1:154977998:T:A	L24Q	0.999
1:154978070:T:A	V48D	0.999
1:154978077:G:C	Q50H	0.999
1:154978077:G:T	Q50H	0.999
1:154978088:G:C	W54S	0.999
1:154978088:G:T	W54L	0.999
1:154978105:C:G	H60D	0.999
1:154978737:T:C	L67S	0.999
1:154978740:T:A	L68Q	0.999
1:154978742:T:C	F69L	0.999
1:154978743:T:C	F69S	0.999
1:154978744:C:A	F69L	0.999
1:154978744:C:G	F69L	0.999
1:154974800:T:C	Y19H	0.998
1:154974804:G:T	R20L	0.998
1:154977998:T:C	L24P	0.998

dbSNP variants (sampled 300 via entrez): RS1001011376 (1:154979097 C>T), RS1001131115 (1:154979607 C>G,T), RS1001555057 (1:154974540 C>A), RS1001890531 (1:154973197 C>T), RS1002352216 (1:154979031 G>A), RS1003094391 (1:154977239 C>G,T), RS1004312072 (1:154975717 T>C), RS1004643005 (1:154974640 C>T), RS1004693996 (1:154974823 G>A,C), RS1004798493 (1:154974295 C>T), RS1005821336 (1:154975560 C>T), RS1005872393 (1:154975872 A>T), RS1006104313 (1:154975178 C>G,T), RS1006588650 (1:154978059 G>T), RS1007089975 (1:154978535 T>G)

Disease associations

OMIM: gene MIM:116900 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): breast neoplasm (MONDO:0021100)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

8 associations (top):

Study	Trait	p-value
GCST001942_19	Prostate cancer	2.000000e-08
GCST007294_124	Body fat distribution (trunk fat ratio)	8.000000e-35
GCST007294_3	Body fat distribution (trunk fat ratio)	6.000000e-21
GCST007294_50	Body fat distribution (trunk fat ratio)	1.000000e-15
GCST007295_17	Body fat distribution (leg fat ratio)	3.000000e-13
GCST007295_37	Body fat distribution (leg fat ratio)	7.000000e-17
GCST007295_72	Body fat distribution (leg fat ratio)	1.000000e-28
GCST008103_81	Bipolar disorder	1.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004341	body fat distribution

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D001943	Breast Neoplasms	C04.588.180; C17.800.090.500

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (3): CHEMBL3632457 (SINGLE PROTEIN), CHEMBL3885558 (PROTEIN-PROTEIN INTERACTION), CHEMBL5482973 (PROTEIN-PROTEIN INTERACTION)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,018 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL238804	SELEXIPAG	4	1,018

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

54 potent at pChembl≥5 of 97 total, top 45 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.77	IC50	170	nM	CHEMBL3633440
6.39	Kd	405.6	nM	CHEMBL5653589
6.27	IC50	540	nM	CHEMBL3633420
6.26	IC50	550	nM	CHEMBL3633421
6.24	IC50	580	nM	CHEMBL3633439
6.24	IC50	570	nM	CHEMBL5411495
6.23	ED50	586.7	nM	CHEMBL5653589
6.08	IC50	840	nM	CHEMBL3633414
5.96	IC50	1100	nM	CHEMBL5420161
5.94	IC50	1150	nM	CHEMBL3633429
5.92	IC50	1210	nM	CHEMBL3633445
5.78	IC50	1670	nM	CHEMBL3633441
5.77	IC50	1700	nM	CHEMBL5393726
5.76	IC50	1730	nM	CHEMBL3633422
5.76	IC50	1740	nM	CHEMBL3633430
5.66	IC50	2180	nM	CHEMBL1487635
5.66	IC50	2200	nM	CHEMBL3633431
5.66	IC50	2200	nM	CHEMBL3633435
5.64	IC50	2300	nM	CHEMBL5420913
5.62	IC50	2400	nM	CHEMBL5428364
5.62	IC50	2400	nM	CHEMBL5406988
5.61	IC50	2450	nM	CHEMBL3633444
5.57	IC50	2700	nM	CHEMBL5399928
5.55	IC50	2800	nM	CHEMBL5410031
5.55	IC50	2800	nM	CHEMBL5417549
5.48	IC50	3300	nM	CHEMBL5427761
5.45	IC50	3570	nM	CHEMBL3633428
5.38	IC50	4200	nM	CHEMBL5422656
5.31	IC50	4860	nM	CHEMBL5593463
5.28	IC50	5200	nM	CHEMBL5433202
5.27	IC50	5400	nM	CHEMBL5409004
5.26	IC50	5540	nM	CHEMBL3633423
5.24	IC50	5800	nM	CHEMBL5400880
5.18	IC50	6550	nM	CHEMBL3633446
5.17	IC50	6700	nM	CHEMBL3633434
5.17	IC50	6700	nM	CHEMBL5414066
5.14	IC50	7160	nM	CHEMBL3633438
5.12	IC50	7600	nM	CHEMBL3633436
5.11	IC50	7840	nM	CHEMBL3633424
5.10	IC50	8020	nM	CHEMBL3633433
5.09	IC50	8120	nM	CHEMBL5404378
5.07	IC50	8500	nM	CHEMBL5420818
5.07	IC50	8500	nM	CHEMBL5408533
5.00	IC50	9900	nM	CHEMBL5429197
5.00	IC50	1e+04	nM	CHEMBL5411594

PubChem BioAssay actives

45 with measured affinity, of 275 total; 44 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
N-(5-pyridin-3-ylquinolin-8-yl)-3-(trifluoromethyl)benzenesulfonamide	1256275: Inhibition of Cks1-Skp2 (unknown origin) interaction after 30 mins by ELISA	ic50	0.1700	uM
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148077: Binding affinity to human CKS1B incubated for 45 mins by Kinobead based pull down assay	kd	0.4057	uM
4-methyl-N-(5-phenylquinolin-8-yl)benzenesulfonamide	1256275: Inhibition of Cks1-Skp2 (unknown origin) interaction after 30 mins by ELISA	ic50	0.5400	uM
N-[5-(furan-2-yl)quinolin-8-yl]-4-methylbenzenesulfonamide	1256275: Inhibition of Cks1-Skp2 (unknown origin) interaction after 30 mins by ELISA	ic50	0.5500	uM
N-[[1-(5,6-diphenylpyrazin-2-yl)piperidin-4-yl]methyl]-2,2-dimethylpropanamide	1989939: Inhibition of GST-tagged Skp2/Skp1 (unknown origin)/His6-tagged Cks1 (unknown origin) interaction preincubated with Skp2/Skp1 for 10 mins followed by Cks1 addition measured after 20 mins by HTRF assay	ic50	0.5700	uM
4-methoxy-N-(5-pyridin-3-ylquinolin-8-yl)benzenesulfonamide	1256275: Inhibition of Cks1-Skp2 (unknown origin) interaction after 30 mins by ELISA	ic50	0.5800	uM
N-(5-bromoquinolin-8-yl)-4-methylbenzenesulfonamide	1256275: Inhibition of Cks1-Skp2 (unknown origin) interaction after 30 mins by ELISA	ic50	0.8400	uM
N-[[1-[5-[4-(hydroxymethyl)phenyl]-6-phenylpyrazin-2-yl]piperidin-4-yl]methyl]-2,2-dimethylpropanamide	1989939: Inhibition of GST-tagged Skp2/Skp1 (unknown origin)/His6-tagged Cks1 (unknown origin) interaction preincubated with Skp2/Skp1 for 10 mins followed by Cks1 addition measured after 20 mins by HTRF assay	ic50	1.1000	uM
N-[6-(4-methoxyphenoxy)quinolin-8-yl]-4-methylbenzenesulfonamide	1256275: Inhibition of Cks1-Skp2 (unknown origin) interaction after 30 mins by ELISA	ic50	1.1500	uM
N-(5-pyridin-4-ylquinolin-8-yl)pyridine-3-sulfonamide	1256275: Inhibition of Cks1-Skp2 (unknown origin) interaction after 30 mins by ELISA	ic50	1.2100	uM
N-(5-pyridin-3-ylquinolin-8-yl)pyridine-3-sulfonamide	1256275: Inhibition of Cks1-Skp2 (unknown origin) interaction after 30 mins by ELISA	ic50	1.6700	uM
tert-butyl 4-(5,6-diphenylpyrazin-2-yl)piperazine-1-carboxylate	1989939: Inhibition of GST-tagged Skp2/Skp1 (unknown origin)/His6-tagged Cks1 (unknown origin) interaction preincubated with Skp2/Skp1 for 10 mins followed by Cks1 addition measured after 20 mins by HTRF assay	ic50	1.7000	uM
4-methyl-N-(5-pyridin-3-ylquinolin-8-yl)benzenesulfonamide	1256275: Inhibition of Cks1-Skp2 (unknown origin) interaction after 30 mins by ELISA	ic50	1.7300	uM
N-[6-(3-cyanophenoxy)quinolin-8-yl]-4-methylbenzenesulfonamide	1256275: Inhibition of Cks1-Skp2 (unknown origin) interaction after 30 mins by ELISA	ic50	1.7400	uM
4-methyl-N-quinolin-8-ylbenzenesulfonamide	1256275: Inhibition of Cks1-Skp2 (unknown origin) interaction after 30 mins by ELISA	ic50	2.1800	uM
N-(5-phenylquinolin-8-yl)methanesulfonamide	1256275: Inhibition of Cks1-Skp2 (unknown origin) interaction after 30 mins by ELISA	ic50	2.2000	uM
N-(5-phenylquinolin-8-yl)pyridine-3-sulfonamide	1256275: Inhibition of Cks1-Skp2 (unknown origin) interaction after 30 mins by ELISA	ic50	2.2000	uM
tert-butyl N-[[1-(5,6-diphenylpyrazin-2-yl)piperidin-4-yl]methyl]carbamate	1989939: Inhibition of GST-tagged Skp2/Skp1 (unknown origin)/His6-tagged Cks1 (unknown origin) interaction preincubated with Skp2/Skp1 for 10 mins followed by Cks1 addition measured after 20 mins by HTRF assay	ic50	2.3000	uM
N-[[1-(5,6-diphenylpyrazin-2-yl)piperidin-4-yl]methyl]morpholine-4-carboxamide	1989939: Inhibition of GST-tagged Skp2/Skp1 (unknown origin)/His6-tagged Cks1 (unknown origin) interaction preincubated with Skp2/Skp1 for 10 mins followed by Cks1 addition measured after 20 mins by HTRF assay	ic50	2.4000	uM
N-[[1-(5,6-diphenylpyrazin-2-yl)piperidin-4-yl]methyl]benzamide	1989939: Inhibition of GST-tagged Skp2/Skp1 (unknown origin)/His6-tagged Cks1 (unknown origin) interaction preincubated with Skp2/Skp1 for 10 mins followed by Cks1 addition measured after 20 mins by HTRF assay	ic50	2.4000	uM
4-methoxy-N-(5-pyridin-4-ylquinolin-8-yl)benzenesulfonamide	1256275: Inhibition of Cks1-Skp2 (unknown origin) interaction after 30 mins by ELISA	ic50	2.4500	uM
2,2-dimethyl-N-[[1-[5-(4-methylsulfonylphenyl)-6-phenylpyrazin-2-yl]piperidin-4-yl]methyl]propanamide	1989939: Inhibition of GST-tagged Skp2/Skp1 (unknown origin)/His6-tagged Cks1 (unknown origin) interaction preincubated with Skp2/Skp1 for 10 mins followed by Cks1 addition measured after 20 mins by HTRF assay	ic50	2.7000	uM
2-chloro-N-[1-(5,6-diphenylpyrazin-2-yl)piperidin-4-yl]acetamide	1989939: Inhibition of GST-tagged Skp2/Skp1 (unknown origin)/His6-tagged Cks1 (unknown origin) interaction preincubated with Skp2/Skp1 for 10 mins followed by Cks1 addition measured after 20 mins by HTRF assay	ic50	2.8000	uM
N-[[1-(5,6-diphenylpyrazin-2-yl)piperidin-4-yl]methyl]propanamide	1989939: Inhibition of GST-tagged Skp2/Skp1 (unknown origin)/His6-tagged Cks1 (unknown origin) interaction preincubated with Skp2/Skp1 for 10 mins followed by Cks1 addition measured after 20 mins by HTRF assay	ic50	2.8000	uM
N-[[1-(5,6-diphenylpyrazin-2-yl)piperidin-4-yl]methyl]cyclopropanecarboxamide	1989939: Inhibition of GST-tagged Skp2/Skp1 (unknown origin)/His6-tagged Cks1 (unknown origin) interaction preincubated with Skp2/Skp1 for 10 mins followed by Cks1 addition measured after 20 mins by HTRF assay	ic50	3.3000	uM
N-[6-(3,5-difluorophenoxy)quinolin-8-yl]-4-methylbenzenesulfonamide	1256275: Inhibition of Cks1-Skp2 (unknown origin) interaction after 30 mins by ELISA	ic50	3.5700	uM
N-[1-(5,6-diphenylpyrazin-2-yl)piperidin-4-yl]benzamide	1989939: Inhibition of GST-tagged Skp2/Skp1 (unknown origin)/His6-tagged Cks1 (unknown origin) interaction preincubated with Skp2/Skp1 for 10 mins followed by Cks1 addition measured after 20 mins by HTRF assay	ic50	4.2000	uM
2-[(4-bromophenyl)methylsulfanyl]-7-(2,4-dimethoxyphenyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidine	2118666: Inhibition of GST-tagged SKP2 (unknown origin) binding to His6-tagged CKS1 (unknown origin) preincubated with SKP2 for 10 mins followed by CKS1 addition for 20 mins and measured after by HTRF method	ic50	4.8600	uM
N-[[1-[5-[4-(dimethylamino)phenyl]-6-phenylpyrazin-2-yl]piperidin-4-yl]methyl]-2,2-dimethylpropanamide	1989939: Inhibition of GST-tagged Skp2/Skp1 (unknown origin)/His6-tagged Cks1 (unknown origin) interaction preincubated with Skp2/Skp1 for 10 mins followed by Cks1 addition measured after 20 mins by HTRF assay	ic50	5.2000	uM
N-[1-(5,6-diphenylpyrazin-2-yl)piperidin-4-yl]acetamide	1989939: Inhibition of GST-tagged Skp2/Skp1 (unknown origin)/His6-tagged Cks1 (unknown origin) interaction preincubated with Skp2/Skp1 for 10 mins followed by Cks1 addition measured after 20 mins by HTRF assay	ic50	5.4000	uM
4-methyl-N-(5-thiophen-3-ylquinolin-8-yl)benzenesulfonamide	1256275: Inhibition of Cks1-Skp2 (unknown origin) interaction after 30 mins by ELISA	ic50	5.5400	uM
cyclopropyl-[4-(5,6-diphenylpyrazin-2-yl)piperazin-1-yl]methanone	1989939: Inhibition of GST-tagged Skp2/Skp1 (unknown origin)/His6-tagged Cks1 (unknown origin) interaction preincubated with Skp2/Skp1 for 10 mins followed by Cks1 addition measured after 20 mins by HTRF assay	ic50	5.8000	uM
N-[4-[(5-pyridin-4-ylquinolin-8-yl)sulfamoyl]phenyl]acetamide	1256275: Inhibition of Cks1-Skp2 (unknown origin) interaction after 30 mins by ELISA	ic50	6.5500	uM
N-(5-phenylquinolin-8-yl)-3-(trifluoromethyl)benzenesulfonamide	1256275: Inhibition of Cks1-Skp2 (unknown origin) interaction after 30 mins by ELISA	ic50	6.7000	uM
N-[[1-[5-(4-fluorophenyl)-6-phenylpyrazin-2-yl]piperidin-4-yl]methyl]-2,2-dimethylpropanamide	1989939: Inhibition of GST-tagged Skp2/Skp1 (unknown origin)/His6-tagged Cks1 (unknown origin) interaction preincubated with Skp2/Skp1 for 10 mins followed by Cks1 addition measured after 20 mins by HTRF assay	ic50	6.7000	uM
N-(5-pyridin-3-ylquinolin-8-yl)cyclopropanesulfonamide	1256275: Inhibition of Cks1-Skp2 (unknown origin) interaction after 30 mins by ELISA	ic50	7.1600	uM
N-[4-[(5-phenylquinolin-8-yl)sulfamoyl]phenyl]acetamide	1256275: Inhibition of Cks1-Skp2 (unknown origin) interaction after 30 mins by ELISA	ic50	7.6000	uM
N-[5-(1-benzothiophen-2-yl)quinolin-8-yl]-4-methylbenzenesulfonamide	1256275: Inhibition of Cks1-Skp2 (unknown origin) interaction after 30 mins by ELISA	ic50	7.8400	uM
4-methoxy-N-(5-phenylquinolin-8-yl)benzenesulfonamide	1256275: Inhibition of Cks1-Skp2 (unknown origin) interaction after 30 mins by ELISA	ic50	8.0200	uM
N-[[1-[5-(furan-2-yl)-6-phenylpyrazin-2-yl]piperidin-4-yl]methyl]-2,2-dimethylpropanamide	1989939: Inhibition of GST-tagged Skp2/Skp1 (unknown origin)/His6-tagged Cks1 (unknown origin) interaction preincubated with Skp2/Skp1 for 10 mins followed by Cks1 addition measured after 20 mins by HTRF assay	ic50	8.1200	uM
N-[[1-(5,6-diphenylpyrazin-2-yl)piperidin-4-yl]methyl]cyclohexanecarboxamide	1989939: Inhibition of GST-tagged Skp2/Skp1 (unknown origin)/His6-tagged Cks1 (unknown origin) interaction preincubated with Skp2/Skp1 for 10 mins followed by Cks1 addition measured after 20 mins by HTRF assay	ic50	8.5000	uM
N-[[1-(5,6-diphenylpyrazin-2-yl)piperidin-4-yl]methyl]thiophene-2-carboxamide	1989939: Inhibition of GST-tagged Skp2/Skp1 (unknown origin)/His6-tagged Cks1 (unknown origin) interaction preincubated with Skp2/Skp1 for 10 mins followed by Cks1 addition measured after 20 mins by HTRF assay	ic50	8.5000	uM
2-chloro-1-[4-(5,6-diphenylpyrazin-2-yl)piperazin-1-yl]ethanone	1989939: Inhibition of GST-tagged Skp2/Skp1 (unknown origin)/His6-tagged Cks1 (unknown origin) interaction preincubated with Skp2/Skp1 for 10 mins followed by Cks1 addition measured after 20 mins by HTRF assay	ic50	9.9000	uM
1-[4-(5,6-diphenylpyrazin-2-yl)piperazin-1-yl]propan-1-one	1989939: Inhibition of GST-tagged Skp2/Skp1 (unknown origin)/His6-tagged Cks1 (unknown origin) interaction preincubated with Skp2/Skp1 for 10 mins followed by Cks1 addition measured after 20 mins by HTRF assay	ic50	10.0000	uM

CTD chemical–gene interactions

74 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Estradiol	increases reaction, increases expression, affects cotreatment, decreases expression	7
bisphenol A	affects cotreatment, decreases methylation, increases expression	3
Resveratrol	affects cotreatment, increases expression, decreases expression	2
Particulate Matter	decreases expression, increases abundance	2
aristolochic acid I	increases expression	1
propionaldehyde	decreases expression	1
deoxynivalenol	increases expression	1
trichostatin A	decreases expression	1
arsenite	increases reaction, affects binding	1
3,3’-diindolylmethane	decreases expression, increases reaction	1
mono-(2-ethylhexyl)phthalate	increases expression	1
sodium arsenite	increases expression	1
cobaltous chloride	decreases expression	1
perfluorooctanoic acid	decreases expression	1
ferrous chloride	increases expression	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	increases expression, affects cotreatment	1
diallyl trisulfide	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
deguelin	increases expression	1
corosolic acid	decreases expression	1
2-palmitoylglycerol	increases expression	1
scriptaid	affects expression	1
fenpyroximate	increases expression	1
pyrimidifen	increases expression	1
ICG 001	increases expression	1
pyrachlostrobin	increases expression	1
jinfukang	increases expression	1
incobotulinumtoxinA	decreases expression	1
picoxystrobin	increases expression	1
Dasatinib	decreases expression	1

ChEMBL screening assays

20 unique, capped per target: 20 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5651119	Binding	Binding affinity to human CKS1B incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00092183	PHASE4	COMPLETED	An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)
NCT00128778	PHASE4	COMPLETED	Maintenance Treatment With Liposomal Doxorubicin (Caelyx) in Metastatic Breast Cancer Patients
NCT00302120	PHASE4	UNKNOWN	The MONET - Study: MR Mammography of Nonpalpable Breast Tumors
NCT00307606	PHASE4	UNKNOWN	Does a Single Steroid Injection Reduce the Formation of Postmastectomy Seroma
NCT00370240	PHASE4	COMPLETED	Chlorhydrate of Ropivacaine and Breast Cancer Surgery
NCT00375752	PHASE4	TERMINATED	Efficacy and Safety of Letrozole vs. Letrozole Plus Zoledronic Acid as Endocrine Therapy Before Surgery in Postmenopausal Patients With Breast Cancer
NCT00575354	PHASE4	COMPLETED	Comparison of Sevoflurane and Isoflurane Anesthesia for Benign Breast Tumor Excision
NCT00604968	PHASE4	TERMINATED	Pegylated Liposomal Doxorubicin (Caelyx(R)) as Monotherapy in Elderly Patients With Locally Advanced and/or Metastatic Breast Cancer (Study P05059)
NCT00616135	PHASE4	COMPLETED	Study of Autologous Fat Enhanced w/ Regenerative Cells Transplanted to Reconstruct Breast Deformities After Lumpectomy
NCT00649090	PHASE4	COMPLETED	A Study to Evaluate the Safety of Adjuvant Treatment With Exemestane Following Previous Treatment With Tamoxifen in Postmenopausal Women With Estrogen Sensitive Primary Breast Cancer
NCT00779285	PHASE4	TERMINATED	Safety Study of CAELYX in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines (Study P04057)(TERMINATED)
NCT01176916	PHASE4	COMPLETED	Aromasin® Interventional Study Of Early Invasive Breast Cancer Patients In China
NCT01427400	PHASE4	UNKNOWN	The Use of Botulinum Toxin A in Two-Stage Tissue Expander/ Implant Breast Reconstruction
NCT01849380	PHASE4	UNKNOWN	Neoadjuvant ECS Versus ECF in Local Advanced Breast Cancer
NCT01859936	PHASE4	COMPLETED	Will Preoperative MRI Breast in Women Under 56 Years With Breast Cancer Change Primary Treatment
NCT01948960	PHASE4	COMPLETED	Influence of Exceptional Patient Characteristics on Everolimus Exposure
NCT01961544	PHASE4	COMPLETED	Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer
NCT01975064	PHASE4	COMPLETED	Cancer and Anesthesia: Survival After Radical Surgery - a Comparison Between Propofol or Sevoflurane Anesthesia
NCT02004834	PHASE4	ACTIVE_NOT_RECRUITING	Levobupivacaine and Lidocaine for Paravertebral Block Causes Greater Hemodynamic Oscillations Than Levobupivacaine
NCT02372305	PHASE4	WITHDRAWN	Comparison of FlexHD and Alloderm Outcomes in Breast Reconstructive Surgery
NCT02479347	PHASE4	COMPLETED	Wound Infections in Breast Cancer Surgery After Preoperative Skin Preparation With Chlorhexidine vs. Povidone-iodine
NCT02549677	PHASE4	COMPLETED	Epirubicin Versus Docetaxel Plus Cyclophosphamide in Lymph Node Negative, ER-positive, Her2-negative Breast Cancer
NCT02612870	PHASE4	UNKNOWN	Sienna+® Injection Time Study 4 Arms
NCT02627560	PHASE4	COMPLETED	The Effect of Topical Tranexamic Acid on Bleeding and Seroma Formation in After Undergoing Mastectomy
NCT02661932	PHASE4	COMPLETED	Fertility Preservation in Breast Cancer Patients
NCT02781259	PHASE4	UNKNOWN	Selective Lymph Node Dissection Using Fluorescent Dye in Node-positive Breast Cancer
NCT02819921	PHASE4	TERMINATED	Desvenlafaxine for Treatment of Hot Flashes in Women With Breast Cancer Taking Tamoxifen
NCT03220178	PHASE4	TERMINATED	Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy
NCT03583944	PHASE4	COMPLETED	A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer
NCT03586154	PHASE4	COMPLETED	Combined Intra-articular Shoulder Injection and Stellate Ganglion Block in Chronic Post-mastectomy Shoulder Pain
NCT04707196	PHASE4	COMPLETED	A Study of Abemaciclib in Indian Women With Advanced Breast Cancer
NCT04931615	PHASE4	COMPLETED	ARTISS a Single-centre Randomised Control Study
NCT05033769	PHASE4	UNKNOWN	Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer
NCT05036005	PHASE4	UNKNOWN	Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON)
NCT05452213	PHASE4	RECRUITING	Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients
NCT05465031	PHASE4	RECRUITING	Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)
NCT05949333	PHASE4	UNKNOWN	Reducing Neutropenia Incidence With Pegfilgrastim Administration on Day 3 After Chemotherapy
NCT07158164	PHASE4	RECRUITING	DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment
NCT07162259	PHASE4	NOT_YET_RECRUITING	Cohort Study on Sequential ADC Therapy in HR-positive/HER2-negative Advanced Breast Cancer
NCT00000611	PHASE3	COMPLETED	Women’s Health Initiative (WHI)